BANTHINE
LOE ApproachingNDAORALTABLET
Approved
Jul 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BANTHINE is an oral small-molecule tablet approved in 1951 by Takeda with unknown mechanism of action and indication. Specific therapeutic use and patient population cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial data suggests small, specialized team managing a legacy asset in transition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate minimal active hiring for this product line. Working on BANTHINE represents a specialized, stable role managing a mature asset with limited growth trajectory or expansion opportunities.
Brand ManagerProduct Manager
Worked on BANTHINE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.